Promising approach

As I am waiting to read the full text, I would like to share this:
Next Generation Sequencing (NGS) is becoming a reliable approach for molecular profiling and treatment decision for non-small cell lung cancer (NSCLC) patients. At least one genetic alteration was found in 78% of the patients. 23% patients showed mutations for which approved (ALK, EGFR, ROS1) or emerging (BRAF, ERBB2, MET, RET) targeted therapies exist.
The details are here: https://www.ncbi.nlm.nih.gov/pubmed/29130105